US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Alumis Inc.

24.17

+1.315.73%

Post-market: 23.83-0.3400-1.41%19:30 EDT

Volume:934.81K

Turnover:22.12M

Market Cap:3.12B

PE:-6.36

High:24.70

Open:22.98

Low:22.21

Close:22.86

52wk High:31.35

52wk Low:3.76

Shares:129.00M

Float Shares:109.67M

Volume Ratio:1.01

T/O Rate:0.85%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-3.8005

EPS(LYR):-2.8616

ROE:-93.65%

ROA:-45.34%

PB:6.90

PE(LYR):-8.45

Loading ...

Overview Company News Filings

What Alumis (ALMS)'s Envudeucitinib Phase 3 Data and Deepening Losses Means For Shareholders

Simply Wall St.

Alumis Publishes Corporate Deck on Next-Generation TYK2 Inhibitors for Immune-Mediated Diseases

Alumis Price Target Maintained with a $25.00/Share by HC Wainwright & Co.

Analysts Offer Insights on Healthcare Companies: Alumis Inc. (ALMS), Cabaletta Bio (CABA) and Capricor Therapeutics (CAPR)

Guggenheim Keeps Their Buy Rating on Alumis Inc. (ALMS)

Alumis Q2 EPS $(1.11) Misses $(0.71) Estimate, Sales $1.662M Miss $3.468M Estimate

Benzinga Earnings

Alumis Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Alumis Q2 FY26 Net Loss Widens to $142.22 Million; Revenue Falls 37.65% to $1.66 Million

Alumis - to Initiate Phase 2 Trial for A-005 in Parkinson's Disease in 1H 2027

THOMSON REUTERS

Alumis - on Track to Submit Nda for Envudeucitinib in Pso to FDA in Q4 2026

THOMSON REUTERS

Press Release: Alumis Reports Second Quarter 2026 Financial Results and Highlights Recent Achievements

Alumis Inc. (ALMS) Receives a Rating Update from a Top Analyst

Alumis reports strong Phase 3 data for envudeucitinib

Alumis - Envudeucitinib Shows Consistent Safety Profile with no New Safety Signals in Onward3

THOMSON REUTERS

Alumis - Topline Data from Lumus Phase 2B Trial in Lupus Expected in Q3 2026

THOMSON REUTERS

Alumis - to Submit Nda to FDA for Envudeucitinib in Q4 2026

THOMSON REUTERS

Alumis - 75% of Patients Achieve Pasi 90, 54% Achieve Pasi 100 After 48 Weeks

THOMSON REUTERS

Alumis Says Envudeucitinib Hits 54% PASI 100 at 48 Weeks in Onward3 Plaque Psoriasis Extension Study

Envudeucitinib Long-term Data Positioned to Set a New Standard for Plaque Psoriasis Treatment, Delivering Highest Reported PASI 100 Skin Clearance Among Oral Therapies

Alumis: Competitive Pressures and Dosing Drawbacks Support Hold Rating and Unchanged $25 Price Target

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/ALMS/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"ALMS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ALMS\",,,,,undefined,":{"symbol":"ALMS","market":"US","secType":"STK","nameCN":"Alumis Inc.","latestPrice":24.17,"timestamp":1787342400000,"preClose":22.86,"halted":0,"volume":934814,"hourTrading":{"tag":"盘后","latestPrice":23.83,"preClose":24.17,"latestTime":"19:30 EDT","volume":15863,"amount":381577.5044,"timestamp":1787355007243,"change":-0.34,"changeRate":-0.014067,"amplitude":0.059164},"delay":0,"changeRate":0.05730533683289599,"floatShares":109674768,"shares":129000000,"eps":-3.800544,"marketStatus":"Market Closed","change":1.31,"latestTime":"08-21 16:00:00 EDT","open":22.98,"high":24.698,"low":22.21,"amount":22124289.6787,"amplitude":0.108836,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.800544,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":7,"adr":0,"listingDate":1719547200000,"exchange":"NASDAQ","adjPreClose":22.86,"preHourTrading":{"tag":"盘前","latestPrice":22.96,"preClose":22.86,"latestTime":"09:29 EDT","volume":499,"amount":11565.89685,"timestamp":1787318999999,"change":0.1,"changeRate":0.004374,"amplitude":0.064742},"postHourTrading":{"tag":"盘后","latestPrice":23.83,"preClose":24.17,"latestTime":"19:30 EDT","volume":15863,"amount":381577.5044,"timestamp":1787355007243,"change":-0.34,"changeRate":-0.014067,"amplitude":0.059164},"volumeRatio":1.013795348835072,"optionData":{"bulkOrders":[{"symbol":"ALMS","call":true,"expireDate":1789704000000,"strike":"35.0","timestamp":1787337187709,"price":2.85,"volume":1680,"amount":478800,"type":"+"}]},"impliedVol":1.9712,"impliedVolPercentile":0.9203},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ALMS\",,,,,undefined,":{"symbol":"ALMS","floatShares":109674768,"roa":"-45.34%","roe":"-93.65%","lyrEps":-2.861649,"volumeRatio":1.013795348835072,"shares":129000000,"dividePrice":0,"high":24.698,"amplitude":0.108836,"preClose":22.86,"low":22.21,"week52Low":3.76,"pbRate":"6.90","psRate":"421.46","week52High":31.35,"institutionHeld":0,"latestPrice":24.17,"eps":-3.800544,"divideRate":0,"volume":934814,"delay":0,"ttmEps":-3.800544,"open":22.98,"prevYearClose":9.76,"prevWeekClose":25.31,"prevMonthClose":28.25,"prevQuarterClose":28.14,"fiveDayClose":25.31,"twentyDayClose":28,"sixtyDayClose":21.33},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ALMS\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-13","symbol":"ALMS","fiscalQuarterEnding":"2026/06","expectedEps":-0.7,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786593600000,"reportTimeType":"post","actualEps":-0.78},{"market":"US","date":"2026-05-14","symbol":"ALMS","fiscalQuarterEnding":"2026/03","expectedEps":-0.79,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778731200000,"reportTimeType":"post","actualEps":-0.74},{"market":"US","date":"2026-03-19","symbol":"ALMS","fiscalQuarterEnding":"2025/12","expectedEps":-0.97,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1773892800000,"reportTimeType":"post","actualEps":-0.95},{"market":"US","date":"2025-11-13","symbol":"ALMS","fiscalQuarterEnding":"2025/09","expectedEps":-0.92,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1763010000000,"reportTimeType":"post","actualEps":-1.06},{"market":"US","date":"2025-08-13","symbol":"ALMS","fiscalQuarterEnding":"2025/06","expectedEps":-1.11,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1755057600000,"reportTimeType":"post","actualEps":-1.17}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ALMS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ALMS\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.6,"buy":0.3,"hold":0.1,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.6,"analysts":10,"updateTime":1778904000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ALMS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ALMS","date":"2026-08-21","current":-6.359616,"percent":0.28757,"low":-16.271116,"twenty":-12.30227,"median":-3.108556,"eighty":-1.162092,"high":-0.443678,"avg":-5.273389,"sd":5.065123,"marketCap":2958889563},"quantilePoints":[{"date":"2024-06-28","current":-4.084559,"twenty":-4.913756,"median":-4.913756,"eighty":-4.416238,"marketCap":689534895},{"date":"2024-07-05","current":-3.516406,"twenty":-4.747917,"median":-3.851156,"eighty":-3.59564,"marketCap":593622147},{"date":"2024-07-12","current":-3.405847,"twenty":-4.063676,"median":-3.825051,"eighty":-3.58397,"marketCap":574958044},{"date":"2024-07-19","current":-4.023985,"twenty":-4.026561,"median":-3.851156,"eighty":-3.52869,"marketCap":679309112},{"date":"2024-07-26","current":-4.023985,"twenty":-4.117224,"median":-3.947896,"eighty":-3.58397,"marketCap":679309112},{"date":"2024-08-02","current":-4.178507,"twenty":-4.123137,"median":-3.980142,"eighty":-3.620209,"marketCap":705394582},{"date":"2024-08-09","current":-3.850149,"twenty":-4.108328,"median":-3.938677,"eighty":-3.693301,"marketCap":649962958},{"date":"2024-08-16","current":-3.683794,"twenty":-4.085032,"median":-3.914533,"eighty":-3.659692,"marketCap":696362265},{"date":"2024-08-23","current":-3.672282,"twenty":-4.078883,"median":-3.855481,"eighty":-3.667968,"marketCap":694186133},{"date":"2024-08-30","current":-3.655014,"twenty":-4.050383,"median":-3.84693,"eighty":-3.659692,"marketCap":690921935},{"date":"2024-09-06","current":-3.442045,"twenty":-4.027205,"median":-3.798947,"eighty":-3.608967,"marketCap":650663491},{"date":"2024-09-13","current":-3.33556,"twenty":-4.023985,"median":-3.741353,"eighty":-3.511116,"marketCap":630534270},{"date":"2024-09-20","current":-3.301025,"twenty":-4.023985,"median":-3.709695,"eighty":-3.405847,"marketCap":624005873},{"date":"2024-09-27","current":-3.211808,"twenty":-3.980142,"median":-3.685233,"eighty":-3.395997,"marketCap":607140850},{"date":"2024-10-04","current":-2.803137,"twenty":-3.959602,"median":-3.672282,"eighty":-3.303903,"marketCap":529888161},{"date":"2024-10-11","current":-2.978693,"twenty":-3.946725,"median":-3.656453,"eighty":-3.263611,"marketCap":563074175},{"date":"2024-10-18","current":-3.462191,"twenty":-3.930629,"median":-3.608967,"eighty":-3.220442,"marketCap":654471723},{"date":"2024-10-25","current":-3.424777,"twenty":-3.915649,"median":-3.608753,"eighty":-3.22332,"marketCap":647399293},{"date":"2024-11-01","current":-3.254977,"twenty":-3.914533,"median":-3.516406,"eighty":-3.231953,"marketCap":615301345},{"date":"2024-11-08","current":-3.459313,"twenty":-3.86344,"median":-3.50536,"eighty":-3.240587,"marketCap":653927690},{"date":"2024-11-15","current":-2.016571,"twenty":-3.859807,"median":-3.465068,"eighty":-3.22332,"marketCap":481504843},{"date":"2024-11-22","current":-2.155567,"twenty":-3.851156,"median":-3.454996,"eighty":-3.18015,"marketCap":514693313},{"date":"2024-11-29","current":-2.109995,"twenty":-3.85035,"median":-3.444923,"eighty":-3.067334,"marketCap":503811848},{"date":"2024-12-06","current":-2.050751,"twenty":-3.847574,"median":-3.439167,"eighty":-2.978693,"marketCap":489665943},{"date":"2024-12-13","current":-1.911755,"twenty":-3.823752,"median":-3.419021,"eighty":-2.94646,"marketCap":456477473},{"date":"2024-12-20","current":-2.009736,"twenty":-3.802749,"median":-3.405847,"eighty":-2.329653,"marketCap":479872624},{"date":"2024-12-27","current":-1.836561,"twenty":-3.764391,"median":-3.395997,"eighty":-2.153744,"marketCap":438523055},{"date":"2025-01-03","current":-1.925427,"twenty":-3.741353,"median":-3.367218,"eighty":-2.142807,"marketCap":459741913},{"date":"2025-01-10","current":-1.595028,"twenty":-3.741353,"median":-3.312536,"eighty":-2.023407,"marketCap":380851289},{"date":"2025-01-17","current":-1.745417,"twenty":-3.740777,"median":-3.298147,"eighty":-1.989684,"marketCap":416760124},{"date":"2025-01-24","current":-1.522113,"twenty":-3.738475,"median":-3.27944,"eighty":-1.964163,"marketCap":363440944},{"date":"2025-01-31","current":-1.704402,"twenty":-3.735597,"median":-3.263611,"eighty":-1.93682,"marketCap":406966805},{"date":"2025-02-07","current":-1.291973,"twenty":-3.709695,"median":-3.247782,"eighty":-1.911755,"marketCap":308489544},{"date":"2025-02-14","current":-1.187157,"twenty":-3.703939,"median":-3.22332,"eighty":-1.873019,"marketCap":283462173},{"date":"2025-02-21","current":-1.178042,"twenty":-3.690125,"median":-3.211808,"eighty":-1.829725,"marketCap":281285880},{"date":"2025-02-28","current":-1.059555,"twenty":-3.68437,"median":-3.162882,"eighty":-1.759544,"marketCap":252994070},{"date":"2025-03-07","current":-1.111963,"twenty":-3.676887,"median":-3.070787,"eighty":-1.711693,"marketCap":265507755},{"date":"2025-03-14","current":-1.041326,"twenty":-3.672858,"median":-3.006033,"eighty":-1.678881,"marketCap":248641484},{"date":"2025-03-21","current":-0.693421,"twenty":-3.667968,"median":-2.978693,"eighty":-1.565406,"marketCap":204027476},{"date":"2025-03-28","current":-1.042906,"twenty":-3.659692,"median":-2.965742,"eighty":-1.505251,"marketCap":306857324},{"date":"2025-04-04","current":-1.85837,"twenty":-3.65559,"median":-2.803137,"eighty":-1.500694,"marketCap":546793636},{"date":"2025-04-11","current":-1.198232,"twenty":-3.63199,"median":-2.286587,"eighty":-1.463027,"marketCap":352559478},{"date":"2025-04-17","current":-0.924562,"twenty":-3.622781,"median":-2.176074,"eighty":-1.280365,"marketCap":272036635},{"date":"2025-04-25","current":-0.791425,"twenty":-3.613572,"median":-2.146452,"eighty":-1.183511,"marketCap":232863359},{"date":"2025-05-02","current":-0.848748,"twenty":-3.60871,"median":-2.125945,"eighty":-1.162092,"marketCap":249729630},{"date":"2025-05-09","current":-0.930109,"twenty":-3.590112,"median":-2.016571,"eighty":-1.140673,"marketCap":273668854},{"date":"2025-05-16","current":-0.890525,"twenty":-3.561975,"median":-1.997203,"eighty":-1.105127,"marketCap":305759157},{"date":"2025-05-23","current":-0.766929,"twenty":-3.530406,"median":-1.968721,"eighty":-1.070948,"marketCap":263322832},{"date":"2025-05-30","current":-0.619565,"twenty":-3.51429,"median":-1.964163,"eighty":-1.045883,"marketCap":212725677},{"date":"2025-06-06","current":-0.530829,"twenty":-3.506511,"median":-1.95277,"eighty":-1.037224,"marketCap":182258572},{"date":"2025-06-13","current":-0.503891,"twenty":-3.48667,"median":-1.925427,"eighty":-0.984896,"marketCap":173009629},{"date":"2025-06-20","current":-0.476954,"twenty":-3.466829,"median":-1.916313,"eighty":-0.943233,"marketCap":163760687},{"date":"2025-06-27","current":-0.522906,"twenty":-3.464493,"median":-1.909477,"eighty":-0.920124,"marketCap":179538295},{"date":"2025-07-03","current":-0.538752,"twenty":-3.462191,"median":-1.878715,"eighty":-0.88573,"marketCap":184978849},{"date":"2025-07-11","current":-0.564105,"twenty":-3.459313,"median":-1.85837,"eighty":-0.848748,"marketCap":193683736},{"date":"2025-07-18","current":-0.556182,"twenty":-3.450679,"median":-1.833144,"eighty":-0.808067,"marketCap":190963459},{"date":"2025-07-25","current":-0.611642,"twenty":-3.444923,"median":-1.819538,"eighty":-0.791425,"marketCap":210005399},{"date":"2025-08-01","current":-0.65601,"twenty":-3.444923,"median":-1.768203,"eighty":-0.766929,"marketCap":225238952},{"date":"2025-08-08","current":-1.301335,"twenty":-3.442045,"median":-1.745417,"eighty":-0.761839,"marketCap":446809517},{"date":"2025-08-15","current":-2.007939,"twenty":-3.439167,"median":-1.743138,"eighty":-0.765537,"marketCap":456842285},{"date":"2025-08-22","current":-2.103991,"twenty":-3.427655,"median":-1.761367,"eighty":-0.766929,"marketCap":478695789},{"date":"2025-08-29","current":-2.14973,"twenty":-3.424777,"median":-1.805264,"eighty":-0.766929,"marketCap":489102219},{"date":"2025-09-05","current":-2.103991,"twenty":-3.415567,"median":-1.826307,"eighty":-0.771366,"marketCap":478695789},{"date":"2025-09-12","current":-1.994217,"twenty":-3.40866,"median":-1.836561,"eighty":-0.773109,"marketCap":453720356},{"date":"2025-09-19","current":-1.9622,"twenty":-3.406179,"median":-1.867544,"eighty":-0.787793,"marketCap":446435855},{"date":"2025-09-26","current":-1.824983,"twenty":-3.405847,"median":-1.875296,"eighty":-0.795863,"marketCap":415216564},{"date":"2025-10-03","current":-1.811262,"twenty":-3.397967,"median":-1.860219,"eighty":-0.799931,"marketCap":412094635},{"date":"2025-10-10","current":-2.071974,"twenty":-3.391392,"median":-1.873019,"eighty":-0.803629,"marketCap":471411288},{"date":"2025-10-17","current":-2.108565,"twenty":-3.371823,"median":-1.884428,"eighty":-0.807327,"marketCap":479736432},{"date":"2025-10-24","current":-2.108565,"twenty":-3.341892,"median":-1.893592,"eighty":-0.812505,"marketCap":479736432},{"date":"2025-10-31","current":-2.131434,"twenty":-3.317141,"median":-1.904969,"eighty":-0.82249,"marketCap":484939647},{"date":"2025-11-07","current":-2.158878,"twenty":-3.30563,"median":-1.911755,"eighty":-0.843135,"marketCap":491183505},{"date":"2025-11-14","current":-2.422653,"twenty":-3.301601,"median":-1.918592,"eighty":-0.848547,"marketCap":551197167},{"date":"2025-11-21","current":-2.946741,"twenty":-3.29642,"median":-1.93682,"eighty":-0.86502,"marketCap":722402348},{"date":"2025-11-28","current":-3.266113,"twenty":-3.290089,"median":-1.953052,"eighty":-0.869088,"marketCap":800697401},{"date":"2025-12-05","current":-3.534386,"twenty":-3.297571,"median":-1.962042,"eighty":-0.870197,"marketCap":866465244},{"date":"2025-12-12","current":-4.943882,"twenty":-3.336738,"median":-1.966442,"eighty":-0.879813,"marketCap":1212007408},{"date":"2025-12-19","current":-4.709675,"twenty":-3.399937,"median":-1.972322,"eighty":-0.888607,"marketCap":1154591037},{"date":"2025-12-26","current":-4.854457,"twenty":-3.410963,"median":-1.990368,"eighty":-0.898223,"marketCap":1190084794},{"date":"2026-01-02","current":-4.156097,"twenty":-3.436865,"median":-1.996504,"eighty":-0.911618,"marketCap":1018879613},{"date":"2026-01-09","current":-7.741582,"twenty":-3.449528,"median":-2.003365,"eighty":-0.920124,"marketCap":1897872066},{"date":"2026-01-16","current":-12.290084,"twenty":-3.466829,"median":-2.013154,"eighty":-0.925671,"marketCap":3012950964},{"date":"2026-01-23","current":-13.362987,"twenty":-3.516406,"median":-2.019374,"eighty":-0.930109,"marketCap":3275976472},{"date":"2026-01-30","current":-13.647739,"twenty":-3.577828,"median":-2.030809,"eighty":-0.937506,"marketCap":3345784190},{"date":"2026-02-06","current":-13.393497,"twenty":-3.626234,"median":-2.053678,"eighty":-0.942816,"marketCap":3283455871},{"date":"2026-02-13","current":-13.6274,"twenty":-3.672282,"median":-2.062826,"eighty":-0.944902,"marketCap":3340797925},{"date":"2026-02-20","current":-14.850306,"twenty":-3.690125,"median":-2.071974,"eighty":-0.965612,"marketCap":3640597141},{"date":"2026-02-27","current":-15.244382,"twenty":-3.739051,"median":-2.087982,"eighty":-0.981145,"marketCap":3737206037},{"date":"2026-03-06","current":-14.054527,"twenty":-3.801818,"median":-2.103991,"eighty":-0.986058,"marketCap":3445509501},{"date":"2026-03-13","current":-12.727381,"twenty":-3.85035,"median":-2.108565,"eighty":-0.99467,"marketCap":3120155674},{"date":"2026-03-20","current":-13.002303,"twenty":-3.914756,"median":-2.117713,"eighty":-1.01599,"marketCap":3163785497},{"date":"2026-03-27","current":-13.758909,"twenty":-3.96371,"median":-2.12686,"eighty":-1.031756,"marketCap":3347886444},{"date":"2026-04-02","current":-11.882219,"twenty":-4.025273,"median":-2.141239,"eighty":-1.038592,"marketCap":2891240839},{"date":"2026-04-10","current":-11.991997,"twenty":-4.096739,"median":-2.146452,"eighty":-1.041326,"marketCap":2917952699},{"date":"2026-04-17","current":-13.068872,"twenty":-4.165061,"median":-2.15037,"eighty":-1.042274,"marketCap":3179983325},{"date":"2026-04-24","current":-13.5864,"twenty":-4.472062,"median":-2.155567,"eighty":-1.044692,"marketCap":3305910664},{"date":"2026-05-01","current":-12.906818,"twenty":-4.742038,"median":-2.161164,"eighty":-1.045883,"marketCap":3140551531},{"date":"2026-05-08","current":-12.420656,"twenty":-4.831463,"median":-2.172599,"eighty":-1.054086,"marketCap":3022256152},{"date":"2026-05-15","current":-13.226323,"twenty":-4.877452,"median":-2.191451,"eighty":-1.062289,"marketCap":3140127467},{"date":"2026-05-22","current":-11.905302,"twenty":-5.029048,"median":-2.200043,"eighty":-1.070948,"marketCap":2826497196},{"date":"2026-05-29","current":-11.491811,"twenty":-7.697296,"median":-2.214811,"eighty":-1.081885,"marketCap":2728328372},{"date":"2026-06-05","current":-10.949441,"twenty":-10.746475,"median":-2.229773,"eighty":-1.094189,"marketCap":2599561472},{"date":"2026-06-12","current":-11.223311,"twenty":-10.767935,"median":-2.309816,"eighty":-1.101025,"marketCap":2664582382},{"date":"2026-06-18","current":-12.377862,"twenty":-10.942997,"median":-2.358363,"eighty":-1.105127,"marketCap":2938690139},{"date":"2026-06-26","current":-13.441123,"twenty":-11.434889,"median":-2.409687,"eighty":-1.106494,"marketCap":3191124259},{"date":"2026-07-02","current":-14.305694,"twenty":-11.51629,"median":-2.443671,"eighty":-1.111963,"marketCap":3396386347},{"date":"2026-07-10","current":-16.271116,"twenty":-11.77244,"median":-2.7977,"eighty":-1.135362,"marketCap":3863006994},{"date":"2026-07-17","current":-14.622524,"twenty":-11.882219,"median":-2.91667,"eighty":-1.139306,"marketCap":3471606615},{"date":"2026-07-24","current":-15.197115,"twenty":-11.985852,"median":-2.970059,"eighty":-1.141585,"marketCap":3608023034},{"date":"2026-07-31","current":-15.546165,"twenty":-12.051591,"median":-2.978693,"eighty":-1.145231,"marketCap":3690892821},{"date":"2026-08-07","current":-14.928615,"twenty":-12.229666,"median":-3.006033,"eighty":-1.151611,"marketCap":3544277044},{"date":"2026-08-14","current":-13.30798,"twenty":-12.354486,"median":-3.070787,"eighty":-1.160269,"marketCap":3159514183},{"date":"2026-08-21","current":-6.740728,"twenty":-12.30227,"median":-3.108556,"eighty":-1.162092,"marketCap":2958889563}],"updateTime":1787467766815},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ALMS\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2660041619","title":"What Alumis (ALMS)'s Envudeucitinib Phase 3 Data and Deepening Losses Means For Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2660041619","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660041619?lang=en_us&edition=fundamental","pubTime":"2026-08-19 09:22","pubTimestamp":1787102572,"startTime":"0","endTime":"0","summary":"Earlier in August 2026, Alumis Inc. reported second-quarter results showing revenue of US$1.66 million and a net loss of US$142.22 million, reversing a net profit a year earlier as loss per share widened sharply.\nA few days before that earnings release, Alumis reported positive topline Phase 3 ONWARD3 extension data for its oral TYK2 inhibitor envudeucitinib in plaque psoriasis and outlined plans to file a U.S. FDA New Drug Application this year, highlighting a potential first-in-class,...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alms/alumis/news/what-alumis-almss-envudeucitinib-phase-3-data-and-deepening","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alms/alumis/news/what-alumis-almss-envudeucitinib-phase-3-data-and-deepening","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ALMS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659126741","title":"Alumis Publishes Corporate Deck on Next-Generation TYK2 Inhibitors for Immune-Mediated Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2659126741","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659126741?lang=en_us&edition=fundamental","pubTime":"2026-08-15 04:07","pubTimestamp":1786738077,"startTime":"0","endTime":"0","summary":"Alumis publishes corporate deck on next-generation TYK2 inhibitors for immune-mediated diseasesAlumis highlighted Phase 3 psoriasis efficacy for envudeucitinib, citing Week 24 PASI 100 of 41% in ONWAR","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nNDL2KXKqr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659112583","title":"Alumis Price Target Maintained with a $25.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2659112583","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659112583?lang=en_us&edition=fundamental","pubTime":"2026-08-15 01:36","pubTimestamp":1786728960,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ALMS/analyst-ratings","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659992141","title":"Analysts Offer Insights on Healthcare Companies: Alumis Inc. (ALMS), Cabaletta Bio (CABA) and Capricor Therapeutics (CAPR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2659992141","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659992141?lang=en_us&edition=fundamental","pubTime":"2026-08-14 20:40","pubTimestamp":1786711234,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Alumis Inc. (ALMS), Cabaletta Bio (CABA) and Capricor Therapeutic...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-alumis-inc-alms-cabaletta-bio-caba-and-capricor-therapeutics-capr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-alumis-inc-alms-cabaletta-bio-caba-and-capricor-therapeutics-capr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","BK4588","XLV","ALMS","CAPR","BK4139","CABA","BK4581","XBI","HCSG","BK4585","BK4007","LU0128526141.USD","LU0029874061.USD","BK4137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659149406","title":"Guggenheim Keeps Their Buy Rating on Alumis Inc. (ALMS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2659149406","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659149406?lang=en_us&edition=fundamental","pubTime":"2026-08-14 20:17","pubTimestamp":1786709870,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Yatin Suneja from Guggenheim reiterated a Buy rating on Alumis Inc., with a price target of $34.00. The company’s s...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/guggenheim-keeps-their-buy-rating-on-alumis-inc-alms-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/guggenheim-keeps-their-buy-rating-on-alumis-inc-alms-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659816019","title":"Alumis Q2 EPS $(1.11) Misses $(0.71) Estimate, Sales $1.662M Miss $3.468M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2659816019","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659816019?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:59","pubTimestamp":1786654767,"startTime":"0","endTime":"0","summary":"Alumis (NASDAQ:ALMS) reported quarterly losses of $(1.11) per share which missed the analyst consensus estimate of $(0.71) by 56.34 percent. This is a 12.6 percent increase over losses of $(1.27) per share from the same","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61196225/alumis-q2-eps-1-11-misses-0-71-estimate-sales-1-662m-miss-3-468m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Alumis Q2 EPS $(1.11) Misses $(0.71) Estimate, Sales $1.662M Miss $3.468M Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659975160","title":"Alumis Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2659975160","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659975160?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:57","pubTimestamp":1786654665,"startTime":"0","endTime":"0","summary":"Alumis Inc. reports results for the quarter ended June 30 - Earnings SummaryAlumis Inc.ALMS.OQreported a quarterly adjusted loss of 79 cents per share for the quarter ended June 30, higher than the sa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL8N44A27H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659164039","title":"Alumis Q2 FY26 Net Loss Widens to $142.22 Million; Revenue Falls 37.65% to $1.66 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2659164039","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659164039?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:01","pubTimestamp":1786651290,"startTime":"0","endTime":"0","summary":"Alumis Q2 FY26 net loss widens to $142.22 million; revenue falls 37.65% to $1.66 millionAlumis posted a net loss of $142.2 million for Q2 2026, swinging from net income of $59.3 million a year earlier","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDL8CQkwM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDF","LU2210149790.SGD","SG9999014005.SGD","SG9999014013.SGD","NDAQ","IE00BGHQF748.EUR","LU0314104364.USD","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","LU2210150020.SGD","LU2095319765.USD","BK4585","IE00BN0W2W23.USD","BK4588","SG9999014021.USD","IE00B64PRP62.GBP","IE00BKPKM429.USD","BK4112","ALMS","IE00B3QW5Z07.USD","BK4007","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659167954","title":"Alumis - to Initiate Phase 2 Trial for A-005 in Parkinson's Disease in 1H 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2659167954","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659167954?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:01","pubTimestamp":1786651261,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nTUA697Z2D:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALMS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659167672","title":"Alumis - on Track to Submit Nda for Envudeucitinib in Pso to FDA in Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2659167672","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659167672?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:01","pubTimestamp":1786651261,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nTUA697Z2D:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ALMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659640971","title":"Press Release: Alumis Reports Second Quarter 2026 Financial Results and Highlights Recent Achievements","url":"https://stock-news.laohu8.com/highlight/detail?id=2659640971","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659640971?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:01","pubTimestamp":1786651260,"startTime":"0","endTime":"0","summary":"that 75% and 54% of patients achieved PASI 90 and PASI 100, respectively,after up to 48 weeks of continuous envudeucitinib treatment , with. envudeucitinib well tolerated and a safety profile consistent with. -- Alumis remains on track to submit its New Drug Application to FDA for. envudeucitinib in PsO in the fourth quarter of 2026.-- Alumis plans to present additional long-term envudeucitinib data at","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLE","ALMS","BK4007","BK4077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659652481","title":"Alumis Inc. (ALMS) Receives a Rating Update from a Top Analyst","url":"https://stock-news.laohu8.com/highlight/detail?id=2659652481","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659652481?lang=en_us&edition=fundamental","pubTime":"2026-08-13 23:35","pubTimestamp":1786635345,"startTime":"0","endTime":"0","summary":"In a report released today, Alex Thompson CFA from Stifel Nicolaus maintained a Buy rating on Alumis Inc., with a price target of $44.00. According...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/alumis-inc-alms-receives-a-rating-update-from-a-top-analyst-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/alumis-inc-alms-receives-a-rating-update-from-a-top-analyst-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658957988","title":"Alumis reports strong Phase 3 data for envudeucitinib","url":"https://stock-news.laohu8.com/highlight/detail?id=2658957988","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658957988?lang=en_us&edition=fundamental","pubTime":"2026-08-11 06:15","pubTimestamp":1786400134,"startTime":"0","endTime":"0","summary":"Alumis Inc. ( ($ALMS) ) has issued an announcement. On August 10, 2026, Alumis reported topline long-term extension data from its Phase 3 ONWARD3 s...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/alumis-reports-strong-phase-3-data-for-envudeucitinib?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/alumis-reports-strong-phase-3-data-for-envudeucitinib?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","ALMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658959748","title":"Alumis - Envudeucitinib Shows Consistent Safety Profile with no New Safety Signals in Onward3","url":"https://stock-news.laohu8.com/highlight/detail?id=2658959748","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658959748?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:20","pubTimestamp":1786393214,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nFWN4471PP:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALMS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658959712","title":"Alumis - Topline Data from Lumus Phase 2B Trial in Lupus Expected in Q3 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2658959712","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658959712?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:20","pubTimestamp":1786393214,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nFWN4471PP:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALMS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658790959","title":"Alumis - to Submit Nda to FDA for Envudeucitinib in Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2658790959","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658790959?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:20","pubTimestamp":1786393214,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nFWN4471PP:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ALMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658597679","title":"Alumis - 75% of Patients Achieve Pasi 90, 54% Achieve Pasi 100 After 48 Weeks","url":"https://stock-news.laohu8.com/highlight/detail?id=2658597679","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658597679?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:20","pubTimestamp":1786393214,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nFWN4471PP:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ALMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658594439","title":"Alumis Says Envudeucitinib Hits 54% PASI 100 at 48 Weeks in Onward3 Plaque Psoriasis Extension Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2658594439","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658594439?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:16","pubTimestamp":1786393015,"startTime":"0","endTime":"0","summary":"Alumis says envudeucitinib hits 54% PASI 100 at 48 weeks in ONWARD3 plaque psoriasis extension studyAlumis reported topline long-term extension results for envudeucitinib in moderate-to-severe plaque ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nNDLbXgvJt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ALMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658952654","title":"Envudeucitinib Long-term Data Positioned to Set a New Standard for Plaque Psoriasis Treatment, Delivering Highest Reported PASI 100 Skin Clearance Among Oral Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2658952654","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658952654?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:05","pubTimestamp":1786392300,"startTime":"0","endTime":"0","summary":"– ONWARD3 data show 54% of patients reached complete skin clearance (PASI 100) after 48 weeks of continuous envudeucitinib treatment –  – Favorable long-term safety and tolerability profile remained c","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/10/3342219/0/en/envudeucitinib-long-term-data-positioned-to-set-a-new-standard-for-plaque-psoriasis-treatment-delivering-highest-reported-pasi-100-skin-clearance-among-oral-therapies.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS","SMP","BK4124","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656320725","title":"Alumis: Competitive Pressures and Dosing Drawbacks Support Hold Rating and Unchanged $25 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2656320725","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656320725?lang=en_us&edition=fundamental","pubTime":"2026-08-03 18:15","pubTimestamp":1785752131,"startTime":"0","endTime":"0","summary":"Analyst Mitchell Kapoor of H.C. Wainwright reiterated a Hold rating on Alumis Inc., retaining the price target of $25.00. Mitchell Kapoor has given...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/alumis-competitive-pressures-and-dosing-drawbacks-support-hold-rating-and-unchanged-25-price-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/alumis-competitive-pressures-and-dosing-drawbacks-support-hold-rating-and-unchanged-25-price-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALMS"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":1,"totalSize":98,"code":"91000000","status":"200"}]}}